Our mission is to improve the life of patients with B cell lymphoma by offering a safe, effective and affordable alternative to current second and third line therapies.

We engineer extracellular vesicles to specifically target B cells and deliver a mRNA-encoded drug to induce apoptosis.

We want to deliver reproducible high-quality science and make cutting-edge science available for patients, doctors and researchers

GET IN TOUCH

info@aab-therapeutics.com

Meditrina Building 260, Babraham Research Campus, Cambridge, CB22 3AT, UK